Compare Citius Pharmaceuticals Inc (CTXR) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Etsy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Etsy Inc trades at $75.59 (market cap $6.90B). The key difference: Etsy Inc is far larger — about 506.6× Citius Pharmaceuticals Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Etsy Inc for 67 Days on average.
| CTXR | ETSY | |
|---|---|---|
Market Cap | $13.62M | $6.90B |
Volume | 132,438 | 2,923,867 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $87.03 |
52-Week Low | $0.48 | $44.05 |
Typical Hold Time | 16 Days | 67 Days |
Enterprise Value | $3.79M | $8.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
ETSY trades at $74.90, up 4.77% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $73 and resistance at $76. Revenue reached $2.88B in 2025, with a net income margin of 5.65%. Recent news highlights AI integration and payment partnerships as growth catalysts, while analyst consensus remains positive with a $85.94 price target.
The outlook for ETSY is cautiously optimistic, supported by consistent earnings outperformance and strategic initiatives. Key risks include high debt levels and competitive e-commerce pressures. Upside potential exists if AI-driven personalization boosts user engagement, but investors should monitor margin sustainability and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
